Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 May 9;3(3):e653.
doi: 10.1097/PR9.0000000000000653. eCollection 2018 May.

First-in-human randomized clinical trials of the safety and efficacy of tanezumab for treatment of chronic knee osteoarthritis pain or acute bunionectomy pain

Patricia A Walicke  1 , Franz Hefti  1 , Roxanne Bales  1 , Shiao-Ping Lu  1 , Jon L Ruckle  2 , Mark T Brown  3 , Christine R West  3 , David L Shelton  1
Affiliations

First-in-human randomized clinical trials of the safety and efficacy of tanezumab for treatment of chronic knee osteoarthritis pain or acute bunionectomy pain

Patricia A Walicke et al. Pain Rep. .

Abstract

Introduction: The neurotrophin nerve growth factor has a demonstrated role in pain transduction and pathophysiology.

Objectives: Two randomized, double-blind, placebo-controlled, phase 1 studies were conducted to evaluate safety, tolerability, and analgesic efficacy of single doses of tanezumab, a humanized anti-nerve growth factor monoclonal antibody, in chronic or acute pain.

Methods: In the first study (CL001), patients with moderate to severe pain from osteoarthritis (OA) of the knee received a single intravenous infusion of tanezumab (3-1000 μg/kg) or placebo in a dose-escalation (part 1; N = 42) or parallel-arm (part 2; N = 79) study design. The second study (CL002) was a placebo-controlled dose-escalation (tanezumab 10-1000 μg/kg; N = 50) study in patients undergoing bunionectomy surgery.

Results: Adverse event rates were generally similar across treatments. Most adverse events were generally mild to moderate in severity and no patients discontinued as a result of adverse events. Adverse events of abnormal peripheral sensation were more common with higher doses of tanezumab (≥100 μg/kg) than with placebo. These were generally mild to moderate in severity. Tanezumab provided up to 12 weeks of effective analgesia for OA knee pain, with statistically significant improvements at doses ≥100 μg/kg (P < 0.05). By contrast, no trend for analgesic activity was found when tanezumab was administered 8 to 16 hours before bunionectomy.

Conclusions: The demonstration of a favorable safety profile and clinical efficacy in OA pain supports clinical development of tanezumab as a potential treatment for chronic pain conditions.

Keywords: Analgesia; Bunionectomy; Nerve growth factor; Osteoarthritis; Safety; Tanezumab.

PubMed Disclaimer

Conflict of interest statement

Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.

Figures

Figure 1.
Figure 1.
CL001 study design (A) part 1 sequential, single-dose, dose-escalation, placebo-controlled, randomized study and (B) part 2 parallel-arm, placebo-controlled, randomized study.
Figure 2.
Figure 2.
CL002 single-dose, dose-escalation, placebo-controlled, randomized study design.
Figure 3.
Figure 3.
Patient disposition in study CL001 (A) part 1 and (B) part 2.
Figure 4.
Figure 4.
Current index knee pain: mean change from baseline visual analogue scale (VAS) in study CL001, part 1. Overall, knee pain was measured on VAS 0 to 100 where higher scores equal greater pain.
Figure 5.
Figure 5.
Patient disposition in study CL002.
Figure 6.
Figure 6.
(A) Mean categorical pain intensity (0–48 hours) and (B) summed categorical pain intensity (days 4–12) after bunionectomy in study CL002.
See this image and copyright information in PMC

References

    1. Abdiche YN, Malashock DS, Pons J. Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors. Protein Sci 2008;17:1326–35. - PMC - PubMed
    1. Balanescu AR, Feist E, Wolfram G, Davignon I, Smith MD, Brown MT, West CR. Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial. Ann Rheum Dis 2014;73:1665–72. - PubMed
    1. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1833–40. - PubMed
    1. Benedict RHB, Schretlen D, Groninger L, Brandt J. Hopkins Verbal Learning Test—revised: normative data and analysis of inter-form and test-retest reliability. Clin Neuropsychol 1998;12:43–55.
    1. Bensen WG, Fiechtner JJ, McMillen JI, Zhao WW, Yu SS, Woods EM, Hubbard RC, Isakson PC, Verburg KM, Geis GS. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc 1999;74:1095–105. - PubMed

LinkOut - more resources